Genmab AS Valuation
| GMAB Stock | DKK 1,510 16.00 1.05% |
At this time, the firm appears to be fairly valued. Genmab AS retains a regular Real Value of kr1494.41 per share. The prevalent price of the firm is kr1509.5. Our model calculates the value of Genmab AS from evaluating the firm fundamentals such as Return On Equity of 0.24, return on asset of 0.1, and Current Valuation of 186.33 B as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Genmab AS's price fluctuation is very steady at this time. Calculation of the real value of Genmab AS is based on 3 months time horizon. Increasing Genmab AS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Genmab AS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Genmab Stock. However, Genmab AS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1509.5 | Real 1494.41 | Hype 1509.5 |
The intrinsic value of Genmab AS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Genmab AS's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Genmab AS helps investors to forecast how Genmab stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Genmab AS more accurately as focusing exclusively on Genmab AS's fundamentals will not take into account other important factors: Genmab AS Total Value Analysis
Genmab AS is currently estimated to have takeover price of 186.33 B with market capitalization of 185.21 B, debt of 378 M, and cash on hands of 18.08 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Genmab AS fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
186.33 B | 185.21 B | 378 M | 18.08 B |
Genmab AS Investor Information
About 50.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.19. Genmab AS recorded earning per share (EPS) of 83.21. The entity had not issued any dividends in recent years. Based on the key indicators related to Genmab AS's liquidity, profitability, solvency, and operating efficiency, Genmab AS is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.Genmab AS Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Genmab AS has an asset utilization ratio of 34.44 percent. This suggests that the Company is making kr0.34 for each dollar of assets. An increasing asset utilization means that Genmab AS is more efficient with each dollar of assets it utilizes for everyday operations.Genmab AS Ownership Allocation
Genmab AS has a total of 65.96 Million outstanding shares. 30% of Genmab AS outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Genmab AS Profitability Analysis
The company reported the revenue of 8.48 B. Net Income was 3.01 B with profit before overhead, payroll, taxes, and interest of 8.48 B.About Genmab AS Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Genmab AS. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Genmab AS based exclusively on its fundamental and basic technical indicators. By analyzing Genmab AS's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Genmab AS's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Genmab AS. We calculate exposure to Genmab AS's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Genmab AS's related companies.Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on Copenhagen Stock Exchange in Denmark.
8 Steps to conduct Genmab AS's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Genmab AS's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Genmab AS's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Genmab AS's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Genmab AS's revenue streams: Identify Genmab AS's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Genmab AS's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Genmab AS's growth potential: Evaluate Genmab AS's management, business model, and growth potential.
- Determine Genmab AS's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Genmab AS's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Information and Resources on Investing in Genmab Stock
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Genmab Stock, please use our How to Invest in Genmab AS guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.